Developing breakthrough AXL therapeutics to improve patients' lives

Developing breakthrough AXL therapeutics to improve patients' lives

Background

Information about the Warrants

Old woman

BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases including cancer and severe respiratory infections

Recent News

30th November 2023

BerGenBio ASA – Final results for the first exercise period for warrants issued in connection with rights issue

29th November 2023

BerGenBio ASA – Preliminary results for the first exercise period for warrants issued in connection with rights issue

28th November 2023

BerGenBio ASA – Last day of the first exercise period for warrants issued in connection with rights issue

24th November 2023

BerGenBio ASA – Information about the first exercise period for warrants issued in connection with rights issue

21st November 2023

BerGenBio ASA Mandatory notification of trade by primary insiders and close associates

15th November 2023

BerGenBio ASA - Commencement of the first exercise period for warrants issued in connection with rights issue

14th November 2023

BerGenBio Reports Third Quarter 2023 Financial Results

6th November 2023

BerGenBio ASA: Invitation to third quarter 2023 results webcast

6th November 2023

BerGenBio Announces Data from Biomarker Analyses in 2L NSCLC